share_log

康哲藥業:自願性及業務進展公告 獲得治療白癜風、化膿性汗腺炎等適應症之口服小分子JAK1抑制劑Povorcitinib獨家許可權利

CMS: Voluntary and Business Update Announcement Gaining Exclusive License for Oral Small-molecule JAK1 Inhibitor Povorcitinib for the Treatment of Vitiligo and Hidradenitis Suppurativa and Other Indications

香港交易所 ·  Apr 1 06:22
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more